Nuclear Medicine is a medical speciality that uses radioactive substances, usually administered in carefully controlled amounts, to diagnose, characterise and sometimes treat disease. Unlike conventional imaging disciplines that primarily depict anatomical structures, nuclear medicine commonly detects physiological, biochemical or molecular processes by observing how a radiopharmaceutical distributes within the body. A radiopharmaceutical generally contains a radionuclide attached to a biologically active molecule or carrier that determines where the compound travels.
Gamma emitting radionuclides can be detected externally for imaging, while certain particulate emissions can deliver therapeutic radiation to selected tissues. The central concept is therefore functional imaging and targeted molecular intervention rather than anatomy alone. Nuclear medicine examinations can investigate bone turnover, myocardial perfusion, renal function, thyroid activity, hepatobiliary processes, pulmonary perfusion and ventilation, infection, inflammation, neurodegeneration and tumour biology. The speciality combines nuclear physics, radiochemistry, pharmacology, physiology, imaging science, medicine and radiation protection.
The historical development of Nuclear Medicine followed discoveries concerning radioactivity, radioactive tracers and the biological behaviour of administered substances. Early work demonstrated that radioactive atoms could be incorporated into biological processes and subsequently detected, establishing the tracer principle that remains fundamental to the field. Developments in radionuclide production, detector technology, radiochemistry and computerised image reconstruction progressively transformed the speciality from relatively simple measurements into sophisticated three dimensional molecular imaging.
The availability of radionuclides from nuclear reactors, cyclotrons and generator systems expanded the range of clinically useful tracers. Technetium 99m became particularly important for diagnostic imaging because its physical characteristics are well suited to gamma camera detection and its generator based availability permits widespread clinical use. More recently, positron emitting radionuclides such as fluorine 18 and radioligands targeting specific receptors or proteins have expanded molecular imaging. Therapeutic nuclear medicine has likewise developed from relatively broad tissue targeting towards increasingly precise radioligand and radionuclide therapies.
A nuclear medicine examination normally begins with selection of an appropriate radiopharmaceutical according to the biological question being investigated. The compound may be administered intravenously, orally, by inhalation or through another route depending on the investigation. After administration, distribution and uptake are measured using specialised detectors. A gamma camera detects single photon emissions and can acquire planar images or tomographic images through single photon emission computed tomography.
Positron emission tomography detects pairs of photons produced following positron annihilation and reconstructs their spatial distribution. Imaging may be combined with computed tomography or magnetic resonance imaging to provide anatomical localisation alongside functional information. The resulting images are interpreted in relation to normal physiology, expected biodistribution, patient history and other investigations. Quantitative methods can estimate tracer uptake, clearance, perfusion or metabolic activity. Timing is important because different radiopharmaceuticals reach target tissues and clear from the body at different rates.
Nuclear medicine depends on the physical properties of radionuclides, particularly their decay modes, half lives, emitted radiation energies and biological behaviour. A physical half life describes the time required for half of a radionuclide population to undergo radioactive decay, while the biological half life describes elimination from the organism through physiological processes. The effective half life combines these processes and influences radiation exposure and imaging or therapeutic duration.
Diagnostic radionuclides are selected to provide useful detectable emissions while minimising unnecessary radiation dose. Therapeutic radionuclides are selected for emissions capable of depositing sufficient energy within diseased tissue. Alpha particles, beta particles and Auger electrons have different ranges and energy deposition characteristics, making them suitable for different therapeutic strategies. Radiation dose is influenced by administered activity, radionuclide properties, biodistribution, tissue uptake and clearance. Nuclear medicine therefore requires careful balancing of diagnostic or therapeutic benefit against radiation exposure.
Radiation protection is an essential component of Nuclear Medicine practice and is based on principles including justification, optimisation and limitation of exposure where applicable. Patients receive radiopharmaceuticals only when the expected clinical information or therapeutic benefit justifies the associated radiation exposure. Staff use appropriate procedures to reduce unnecessary occupational exposure, including minimising time near sources, maximising distance where practical and using suitable shielding and handling procedures.
Contamination control is particularly important because radioactive material may be present in bodily fluids after administration. Imaging facilities require controlled areas, appropriate waste management, contamination monitoring and procedures for accidental spills or unexpected exposures. Patients may receive instructions concerning hydration, urination, contact with vulnerable individuals or other precautions depending on the radionuclide and administered activity. Pregnancy and breastfeeding require particular consideration because radiation exposure can affect a developing fetus or may result in radioactive substances entering breast milk.
Therapeutic Nuclear Medicine uses radioactive substances to deliver ionising radiation to diseased tissue. Radioiodine therapy is a classic example because thyroid tissue actively concentrates iodine, allowing radioactive iodine to selectively irradiate thyroid cells. Other therapeutic approaches use radiolabelled molecules that bind to tumour associated receptors or antigens, creating forms of targeted radionuclide therapy. Peptide receptor radionuclide therapy can deliver radiation to tumours expressing particular receptors, while radioligand therapy can exploit molecular targets expressed by specific cancers.
The therapeutic principle depends on sufficient uptake in diseased tissue relative to surrounding normal tissue, adequate retention, appropriate radiation emission and manageable toxicity to healthy organs. Kidney, bone marrow and other normal tissues can become dose limiting organs depending on the treatment. Dosimetry attempts to estimate absorbed radiation doses and can help personalise treatment. This represents a major conceptual shift from treating anatomical regions broadly towards delivering radiation according to biological targeting.
Nuclear Medicine has applications across many organ systems. Bone scintigraphy can identify areas of altered bone turnover and is useful in investigating selected metastatic, traumatic and inflammatory processes. Myocardial perfusion imaging evaluates regional blood flow to cardiac muscle under specified physiological conditions. Renal nuclear medicine can assess perfusion, filtration, drainage and differential renal function. Thyroid imaging evaluates functional tissue distribution, while hepatobiliary studies can examine bile production and flow. Lung studies can investigate ventilation and perfusion.
In oncology, molecular tracers can help identify metabolically active or receptor expressing tumour tissue and can be used for staging, treatment selection and response assessment. Neurological nuclear medicine can examine cerebral perfusion, glucose metabolism or particular protein targets. These applications illustrate the defining advantage of the speciality: the imaging target can be a biological process rather than merely a visible structural abnormality.
Nuclear Medicine differs from several related medical technologies in important ways. Conventional radiography and computed tomography primarily measure X ray attenuation and therefore provide detailed anatomical information, whereas nuclear medicine measures emitted radiation originating from administered tracers and therefore commonly reflects physiology. Magnetic resonance imaging uses magnetic fields and radiofrequency signals rather than ionising radiation, although particular functional MRI techniques can also provide physiological information through different mechanisms. Ultrasound uses acoustic waves and is likewise non ionising.
Nuclear medicine can provide information that is difficult or impossible to infer reliably from anatomy alone, but its spatial resolution is often lower than that of CT or MRI. Hybrid systems address this limitation by combining modalities. The future of Nuclear Medicine increasingly involves quantitative imaging, artificial intelligence, theranostics, novel radiopharmaceuticals and personalised dosimetry. Its distinctive contribution is the ability to visualise and manipulate biological processes using radioactive molecular probes and targeted radioactive therapies.
